Abstract
Purpose
The aim of our study was to evaluate the pharmacology of vorapaxar (SCH 530348), an oral PAR-1 antagonist, in healthy volunteers.
Methods and results
In two randomized, placebo-controlled studies, subjects received either single ascending doses of vorapaxar (0.25, 1, 5, 10, 20, or 40 mg; n = 50), multiple ascending doses of vorapaxar (1, 3, or 5 mg/day for 28 days; n = 36), a loading dose (10 or 20 mg) followed by daily maintenance doses (1 mg) for 6 days (n = 12), or placebo. Single 20- and 40-mg doses of vorapaxar completely inhibited thrombin receptor activating peptide (TRAP)-induced platelet aggregation (>80% inhibition) at 1 h and sustained this level of inhibition for ≥72 h. Multiple doses yielded complete inhibition on Day 1 (5 mg/day) and Day 7 (1 and 3 mg/day). Adverse events were generally mild, transient, and unrelated to dose.
Conclusion
Vorapaxar provided rapid and sustained dose-related inhibition of platelet aggregation without affecting bleeding or clotting times.
Similar content being viewed by others
References
Davi G, Patrono C (2007) Platelet activation and atherothrombosis. N Engl J Med 357:2482–2494
Angiolillo DJ, Capodanno D, Goto S (2010) Platelet thrombin receptor antagonism and atherothrombosis. Eur Heart J 31:17–28
Bhatt DL, Fox KA, Hacke W, Berger PB, Black HR, Boden WE, Cacoub P, Cohen EA, Creager MA, Easton JD, Flather MD, Haffner SM, Hamm CW, Hankey GJ, Johnston SC, Mak KH, Mas JL, Montalescot G, Pearson TA, Steg PG, Steinhubl SR, Weber MA, Brennan DM, Fabry-Ribaudo L, Booth J, Topol EJ (2006) CHARISMA Investigators. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med 354:1706–1717
Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S, Neumann FJ, Ardissino D, De Servi S, Murphy SA, Riesmeyer J, Weerakkody G, Gibson CM, Antman EM (2007) TRITON-TIMI 38 investigators. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 357:2001–2015
Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK (2001) Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 345:494–502
García Rodríguez LA, Hernández-Díaz S, de Abajo FJ (2001) Association between aspirin and upper gastrointestinal complications: systematic review of epidemiologic studies. Br J Clin Pharmacol 52:563–571
Rao SV, O'Grady K, Pieper KS, Granger CB, Newby LK, Van de Werf F, Mahaffey KW, Califf RM, Harrington RA (2005) Impact of bleeding severity on clinical outcomes among patients with acute coronary syndromes. Am J Cardiol 96:1200–1206
Brummel KE, Paradis SG, Butenas S, Mann KG (2002) Thrombin functions during tissue factor-induced blood coagulation. Blood 100:148–152
Mann KG (2003) Thrombin formation. Chest 124[Suppl 3]:4S–10S
Chintala M, Shimizu K, Ogawa M, Yamaguchi H, Doi M, Jensen P (2008) Basic and translational research on proteinase-activated receptors: antagonism of the proteinase-activated receptor 1 for thrombin, a novel approach to antiplatelet therapy for atherothrombotic disease. J Pharmacol Sci 108:433–438
Derian CK, Damiano BP, Addo MF, Darrow AL, D'Andrea MR, Nedelman M, Zhang HC, Maryanoff BE, Andrade-Gordon P (2003) Blockade of the thrombin receptor protease-activated receptor-1 with a small-molecule antagonist prevents thrombus formation and vascular occlusion in nonhuman primates. J Pharmacol Exp Ther 304:855–861
Kato Y, Kita Y, Hirasawa-Taniyama Y, Nishio M, Mihara K, Ito K, Yamanaka T, Seki J, Miyata S, Mutoh S (2003) Inhibition of arterial thrombosis by a protease-activated receptor 1 antagonist, FR171113, in the guinea pig. Eur J Pharmacol 473:163–169
Chackalamannil S, Wang Y, Greenlee WJ, Hu Z, Xia Y, Ahn HS, Boykow G, Hsieh Y, Palamanda J, Agans-Fantuzzi J, Kurowski S, Graziano M, Chintala M (2008) Discovery of a novel, orally active himbacine-based thrombin receptor antagonist (SCH 530348) with potent antiplatelet activity. J Med Chem 51:3061–3064
Hildemann SK, Bode C (2009) Improving antiplatelet therapy for atherothrombotic disease: preclinical results with SCH 530348, the first oral thrombin receptor antagonist selective for PAR-1. Hämostaseologie 29:349–355
Becker RC, Moliterno DJ, Jennings LK, Pieper KS, Pei J, Niederman A, Ziada KM, Berman G, Strony J, Joseph D, Mahaffey KW, Van de Werf F, Veltri E, Harrington RA (2009) TRA-PCI Investigators. Safety and tolerability of SCH 530348 in patients undergoing non-urgent percutaneous coronary intervention: a randomised, double-blind, placebo-controlled phase II study. Lancet 373:919–928
Ozaki Y, Satoh K, Yatomi Y, Yamamoto T, Shirasawa Y, Kume S (1994) Detection of platelet aggregates with a particle counting method using light scattering. Anal Biochem 218:284–294
Mielke CH Jr, Kaneshiro MM, Maher IA, Weiner JM, Rapaport SI (1969) The standardized normal Ivy bleeding time and its prolongation by aspirin. Blood 34:204–215
Kosoglou T, Reyderman L, Tiessen R, Fales RR, Cutler DL, Keller R, Yang B, Van Lier JJ, Wadham A, Van Vliet AA (2009) TRAP-induced platelet aggregation following single and multiple rising oral doses of SCH 530348, a novel thrombin receptor antagonist, in healthy volunteers. Clin Pharmacol Ther 85(S1):S21, Abstract PI-40
Kosoglou T, Reyderman L, Kasserra C, Young S, Pei J, Maxwell SE, Schiller J, Cutler DL (2008) Optimizing dose of the novel thrombin receptor antagonist SCH 530348 based on pharmacodynamics and pharmacokinetics in healthy subjects. Clin Pharmacol Ther 83(S1):S55, Abstract PII-42
Jennings LK, Earhart A, Becker RC, Reyderman L, Veltri E, Strony J, Harrington RA (2007) Thrombin receptor antagonist (TRA;SCH 530348) is a selective, potent inhibitor of PAR1 activity with predictable pharmacokinetics (abstract). Circulation 116[Suppl]:II-674, Abstract 3010
Chintala M, Vemulapalli S, Kurowski S, Sabin C, Reynolds D, Prevete K, Friedrichs G (2008) SCH 530348, a novel oral antiplatelet agent, demonstrated no bleeding risk alone or in combination with aspirin and clopidogrel in cynomolgus monkeys (abstract). Arterioscl Thromb Vasc Biol 28:e138–e139, Abstract P579
Goto S, Yamaguchi T, Ikeda Y, Kato K, Yamaguchi H, Jensen P (2010) Safety and exploratory efficacy of the novel thrombin receptor (PAR-1) antagonist SCH530348 for non-ST-segment elevation acute coronary syndrome. J Atheroscler Thromb 17:156–164
Vandendries ER, Hamilton JR, Coughlin SR, Furie B, Furie BC (2007) Par4 is required for platelet thrombus propagation but not fibrin generation in a mouse model of thrombosis. Proc Natl Acad Sci USA 104:288–292
Acknowledgments
The authors thank Joshua Barbach and Sean Gregory for assisting with the electronic submission of the manuscript and for providing editorial support. This assistance was funded by Schering-Plough Corporation (now Merck, Whitehouse Station, NJ, USA). The authors also wish to thank Alan Meehan of Merck for editorial support.
Conflict of interest
T Kosoglou, L Reyderman, RR Fales, R Keller, B Yang, and DL Cutler all declare that they are/were full-time employees of Schering-Plough Corporation (now Merck) at the time of the study. RG Tiessen and AA van Vliet are full-time employees of PRA International, and funding was provided to PRA International from Schering-Plough Corporation (now Merck) to conduct each study.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Kosoglou, T., Reyderman, L., Tiessen, R.G. et al. Pharmacodynamics and pharmacokinetics of the novel PAR-1 antagonist vorapaxar (formerly SCH 530348) in healthy subjects. Eur J Clin Pharmacol 68, 249–258 (2012). https://doi.org/10.1007/s00228-011-1120-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00228-011-1120-6